OPR - Delayed Quote USD

ARGX Dec 2024 280.000 put (ARGX241220P00280000)

14.40

0.00

(0.00%)

At close: January 24 at 11:02 AM EST

Key Events

Loading Chart for ARGX241220P00280000

9/21 12:03 PM

DELL

Previous Close 14.40
Open 14.50
Bid 6.50
Ask 11.40
Strike 280.00
Expire Date 2024-12-20
Day's Range 14.40 - 14.50
Contract Range --
Volume 16
Open Interest 20

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Reasons to Invest in argenx (ARGX)

Reasons to Invest in argenx (ARGX)

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Should You be Confident in Your Investment in argenx SE (ARGX)?

Should You be Confident in Your Investment in argenx SE (ARGX)?